Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

UFS Expert: Prof Felicity Burt investigates zoonotic and arboviruses
2017-12-13


 Description: Burt read more 2 Tags: Arboviruses, Felicity Burt, Crimean-Congo haemorrhagic fever, viruses  

Prof Felicity Burt recently received a B-rating from the
National Research
Foundation.
Photo: Sonia Small

Prof Felicity Burt is from the Division of Virology in the Faculty of Health Sciences at the University of the Free State (UFS), as well as the National Health Laboratory Services (NHLS). She currently holds an NRF-DST South African Research Chair in vector-borne and zoonotic diseases.  Professor Burt and her research group investigate arboviruses and zoonotic viruses. 

Prof Burt’s research primarily focuses on host immune responses to arboviral infections specifically characterising humoral and cellular immune responses in patients with infections such as Crimean-Congo haemorrhagic fever (CCHF) virus and Sindbis virus; epitope discovery for development of diagnostic tools; development of molecular and serological assays for surveillance purposes; virus discovery; and the development of vaccines.

Raising awareness of these viruses, defining associated diseases, and developing tools for surveillance programmes will contribute to understanding these pathogens as well as the public health implications.

Leads research group in papilloma viruses
Arboviruses cause outbreaks of disease in South Africa annually. Outbreaks are usually associated with heavy rainfall favouring the breeding of mosquitos, but these viruses also have the capacity to spread and become endemic in new areas where competent vectors are present. 
In addition, she is leading a research group that investigates human papilloma viruses (HPV) associated with head and neck cancers and recurrent laryngeal papilloma.

The focus of this research group is to ascertain the genotypes of HPV causing these diseases, identification of novel biomarkers for early detection, and complete genome sequencing for molecular characterisation of HPV isolates.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept